Metastatic prostate cancer—a review of current treatment options and promising new approaches
P Posdzich, C Darr, T Hilser, M Wahl, K Herrmann… - Cancers, 2023 - mdpi.com
Simple Summary Prostate cancer is the most common tumor in men. Although there have
been many new developments in the last few years, metastatic castration resistant prostate …
been many new developments in the last few years, metastatic castration resistant prostate …
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with
an aggressive disease course despite currently approved therapeutics. The recent …
an aggressive disease course despite currently approved therapeutics. The recent …
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
E Schaeffer, S Srinivas, ES Antonarakis… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …
prostate cancer diagnosis and include management options for localized, regional, and …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Xaluritamig, a STEAP1× CD3 XmAb 2+ 1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study
WK Kelly, DC Danila, CC Lin, JL Lee, N Matsubara… - Cancer Discovery, 2024 - AACR
Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …
Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …
regarding the workup of patients with prostate cancer, risk stratification and management of …
NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional …
prostate cancer diagnosis and include management options for localized, regional …
[HTML][HTML] LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
LC Brown, MD Tucker, R Sedhom… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Low-density lipoprotein receptor-related protein 1b (encoded by LRP1B) is a
putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may …
putative tumor suppressor, and preliminary evidence suggests LRP1B-mutated cancers may …
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
ABSTRACT PT-112 is a novel platinum-pyrophosphate conjugate under clinical
development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a …
development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a …
Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study
DP Petrylak, Y Loriot, DR Shaffer, F Braiteh… - Clinical Cancer …, 2021 - AACR
Purpose: Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and
efficacious in multiple cancers, but has not been previously evaluated in metastatic …
efficacious in multiple cancers, but has not been previously evaluated in metastatic …